241
Participants
Start Date
June 10, 2019
Primary Completion Date
September 18, 2020
Study Completion Date
September 18, 2020
AF03
A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether
Delta Inulin-CpG55.2
A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)
Influenza Virus Quadrivalent Inactivated Vaccine
2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
Quadrivalent Recombinant Seasonal Influenza Vaccine
2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
Duke Vaccine and Trials Unit, Durham
Emory University School of Medicine, Atlanta
University of Iowa - Vaccine Research and Education Unit, Iowa City
University of Maryland Baltimore - School of Medicine - Medicine, Baltimore
Saint Louis University Center for Vaccine Development, St Louis
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville
Baylor College of Medicine, Houston
National Institute of Allergy and Infectious Diseases (NIAID)
NIH